Evaluating the impact of specific antibodies in patients with dilated cardiomyopathy
Official title: DCM Anti-Heart Antibody Diagnostic Kit Study--assessment of the Prognostic Impact of Anti-beta1AR Antibody and Anti-L-CaC Antibody in Patients With Dilated Cardiomyopathy
Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT06741995 · Data updated 2026-11-12
This study is trying to see if certain antibodies in people with dilated cardiomyopathy can help predict their heart health and outcomes over three years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | December 17, 2024 |
| Main results expected | December 17, 2027 |
| Study ends | December 17, 2027 |
| Registry record updated | April 11, 2025 |
| Trial ID | NCT06741995 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-75 who have been diagnosed with dilated cardiomyopathy.
✕Probably not a fit
Patients with serious uncontrolled infections, active bleeding, or other severe comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the prognostic significance of anti-β1AR and anti-L-CaC antibodies in patients diagnosed with dilated cardiomyopathy (DCM). Conducted as a multicenter, prospective cohort study in China, it will follow DCM patients over a period of three years to evaluate the relationship between these antibodies and clinical outcomes such as cardiovascular death and ventricular tachycardia. The study seeks to provide valuable epidemiological data and identify potential therapeutic targets for DCM management.
Why it matters
Potential benefit: If successful, this study could enhance the prognostic evaluation and treatment strategies for patients with dilated cardiomyopathy.
How similar studies have gone: Previous studies have suggested associations between these antibodies and adverse outcomes in DCM, but this study aims to provide more robust multicenter data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Age 18-75, any gender
2. Diagnosed with dilated cardiomyopathy
3. Subjects or their legal guardians are fully informed of the nature and risks of the study, participate voluntarily, and sign an informed consent form.
Exclusion Criteria:
1. Serious uncontrolled infection at enrolment ("uncontrolled" is defined as signs and symptoms of infection that persist without improvement despite antimicrobial or other treatment)
2. Uncontrolled active bleeding at enrollment
3. Pregnancy or breastfeeding
4. Combination of serious diseases affecting survival, such as tumors, with a life expectancy of less than one year
5. Previous heart transplant or implantation of a cardiac assist device
6. Patients with poor compliance who are unable to complete the full course of the study
7. Other conditions (e.g., overstimulation, sensitivity, cognitive impairment, mental illness, or substance abuse/addiction) that, in the judgment of the investigator, may increase the risk to the subject or interfere with the clinical study and judgment of the results.
Where it's running
-
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Jing Yuan
- Email: yhelen13@163.com
- Phone: 86-13886121012
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Second infusion of FAP-targeted iCDC for end-stage dilated cardiomyopathy
This study tests whether a second dose of FAP-targeted immunosuppressive CAR-DC therapy can safely improve heart function in adults with end-stage dilated cardiomyopathy who previously had a partial response.
-
AAV Gene Therapy for BAG3-Related Dilated Cardiomyopathy in Adults
This Phase 1/2 trial tests a single IV dose of AFTX-201 to see if it is safe and potentially helps adults with BAG3-related dilated cardiomyopathy.
-
Monitoring progression of chronic cardiovascular conditions
This project will collect wearable physiologic data from adults with cardiovascular conditions to see how their heart disease changes over time.
-
Multimodal analysis of heart biopsy samples
This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.
-
T1 mapping to characterize heart tissue in common heart diseases
This project tests whether T1 mapping MRI scans, including dye-free native T1, can define normal and disease-specific heart tissue values for adults with various heart conditions.
-
Endocardial delivery of stem-cell derived heart cells to help severe heart failure
This study tests endocardial delivery of HS-001 cell sheets made from iPSC-derived cardiomyocytes in adults with severe heart failure and reduced ejection fraction to see if it is safe and may improve heart function over 26 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.